Cargando…

Safe medication use based on knowledge of information about contraindications concerning cross allergy and comprehensive clinical intervention

BACKGROUND: An investigation of safety issues regarding information on contraindications related to cross allergy was conducted to promote clinical awareness and prevent medical errors in a 2200-bed tertiary care teaching hospital. METHODS: Prescribing information on contraindications concerning cro...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wei, Zhu, Ling-Ling, Zhou, Quan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585575/
https://www.ncbi.nlm.nih.gov/pubmed/23459439
http://dx.doi.org/10.2147/TCRM.S42013
_version_ 1782261184550928384
author Li, Wei
Zhu, Ling-Ling
Zhou, Quan
author_facet Li, Wei
Zhu, Ling-Ling
Zhou, Quan
author_sort Li, Wei
collection PubMed
description BACKGROUND: An investigation of safety issues regarding information on contraindications related to cross allergy was conducted to promote clinical awareness and prevent medical errors in a 2200-bed tertiary care teaching hospital. METHODS: Prescribing information on contraindications concerning cross allergy was collected from an information system and package inserts. Data mining and descriptive analysis were performed. A risk register was used for project management and risk assessment. A Plan, Do, Check, Act cycle was used as part of continuous quality improvement. Records of drug counseling and medical errors were collected from an online reporting system. A pharmacist-led multidisciplinary team initiated an intervention program on cross allergy in August 2008. RESULTS: Four years of risk management at our hospital achieved successful outcomes, ie, the number of medical errors related to cross allergies decreased by 97% (10 cases monthly before August 2008 versus three cases yearly in 2012) and risk rating decreased significantly [initial risk rating: 25(high-risk) before August 2008 versus final risk rating:6 (medium-risk) in December 2012]. CONCLUSION: We conclude that comprehensive clinical interventions are very effective through team cooperation. Medication use has potential for safety risks if sufficient attention is not paid to contraindications concerning cross allergy. The potential for cross allergy involving drugs which belong to completely different pharmacological classes is easily overlooked and can be dangerous. Pharmacists can play an important role in reducing the risk of cross allergy as well as recommending therapeutic alternatives.
format Online
Article
Text
id pubmed-3585575
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-35855752013-03-04 Safe medication use based on knowledge of information about contraindications concerning cross allergy and comprehensive clinical intervention Li, Wei Zhu, Ling-Ling Zhou, Quan Ther Clin Risk Manag Short Report BACKGROUND: An investigation of safety issues regarding information on contraindications related to cross allergy was conducted to promote clinical awareness and prevent medical errors in a 2200-bed tertiary care teaching hospital. METHODS: Prescribing information on contraindications concerning cross allergy was collected from an information system and package inserts. Data mining and descriptive analysis were performed. A risk register was used for project management and risk assessment. A Plan, Do, Check, Act cycle was used as part of continuous quality improvement. Records of drug counseling and medical errors were collected from an online reporting system. A pharmacist-led multidisciplinary team initiated an intervention program on cross allergy in August 2008. RESULTS: Four years of risk management at our hospital achieved successful outcomes, ie, the number of medical errors related to cross allergies decreased by 97% (10 cases monthly before August 2008 versus three cases yearly in 2012) and risk rating decreased significantly [initial risk rating: 25(high-risk) before August 2008 versus final risk rating:6 (medium-risk) in December 2012]. CONCLUSION: We conclude that comprehensive clinical interventions are very effective through team cooperation. Medication use has potential for safety risks if sufficient attention is not paid to contraindications concerning cross allergy. The potential for cross allergy involving drugs which belong to completely different pharmacological classes is easily overlooked and can be dangerous. Pharmacists can play an important role in reducing the risk of cross allergy as well as recommending therapeutic alternatives. Dove Medical Press 2013 2013-02-26 /pmc/articles/PMC3585575/ /pubmed/23459439 http://dx.doi.org/10.2147/TCRM.S42013 Text en © 2013 Li et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Short Report
Li, Wei
Zhu, Ling-Ling
Zhou, Quan
Safe medication use based on knowledge of information about contraindications concerning cross allergy and comprehensive clinical intervention
title Safe medication use based on knowledge of information about contraindications concerning cross allergy and comprehensive clinical intervention
title_full Safe medication use based on knowledge of information about contraindications concerning cross allergy and comprehensive clinical intervention
title_fullStr Safe medication use based on knowledge of information about contraindications concerning cross allergy and comprehensive clinical intervention
title_full_unstemmed Safe medication use based on knowledge of information about contraindications concerning cross allergy and comprehensive clinical intervention
title_short Safe medication use based on knowledge of information about contraindications concerning cross allergy and comprehensive clinical intervention
title_sort safe medication use based on knowledge of information about contraindications concerning cross allergy and comprehensive clinical intervention
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585575/
https://www.ncbi.nlm.nih.gov/pubmed/23459439
http://dx.doi.org/10.2147/TCRM.S42013
work_keys_str_mv AT liwei safemedicationusebasedonknowledgeofinformationaboutcontraindicationsconcerningcrossallergyandcomprehensiveclinicalintervention
AT zhulingling safemedicationusebasedonknowledgeofinformationaboutcontraindicationsconcerningcrossallergyandcomprehensiveclinicalintervention
AT zhouquan safemedicationusebasedonknowledgeofinformationaboutcontraindicationsconcerningcrossallergyandcomprehensiveclinicalintervention